Advagene Biopharma Co., Ltd. (TPEX:6709)
Taiwan
· Delayed Price · Currency is TWD 26.50
0.00 (0.00%)
Apr 29, 2026, 12:13 PM CST
Advagene Biopharma Market Cap
Advagene Biopharma has a market cap or net worth of 1.57 billion as of April 29, 2026. Its market cap has increased by 23.83% in one year.
Market Cap
1.57B
Enterprise Value
1.44B
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
26.50
Market Cap Chart
Since November 29, 2018, Advagene Biopharma's market cap has increased from 1.16B to 1.57B, an increase of 35.80%. That is a compound annual growth rate of 4.21%.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| GenMont Biotech Incorporation | 1.54B |
| Bio Preventive Medicine | 1.70B |
| NeoCore Technology | 1.42B |
| Andros Pharmaceuticals Co.,Ltd | 1.71B |
| Enimmune | 1.36B |
| Meribank Biotech | 1.34B |
| Great Novel Therapeutics Biotech & Medicals | 1.81B |
| Abnova (Taiwan) | 1.31B |